Oculus Innovative Sciences has obtained 510(k) approval from the US Food and Drug Administration (FDA) for its new Microcyn scar management HydroGel, intended to manage old and new hypertrophic and keloid scarring resulting from burns, ...
Oculus Innovative Sciences has enrolled first patient, under an FDA-reviewed protocol, in a clinical study of its Microcyn hydrogel. Microcyn hydrogel is indicated for use in hypertrophic or keloid scars management. The double-blind, ...
Tags: Oculus Innovative Sciences, Microcyn hydrogel, keloid scars management
The Chinese State Food and Drug Administration (SFDA) has granted approval to Oculus Innovative Sciences' Microcyn hydrogel for moistening, repairing and healing acute and chronic wounds. The approval is based on the completion of ...
Tags: SFDA, Oculus Microcyn Hydrogel, healing acute, chronic wounds
AmDerma Pharmaceuticals and Oculus Innovative Sciences have signed a multi-country agreement to develop and commercialize Microcyn technology drug compounds for major dermatological conditions. The agreement includes licensing of the ...
Tags: Microcyn technology drug compounds, dermatology compounds